Niagen Bioscience (NAGE) A.G.P. Virtual Consumer Showcase summary
Event summary combining transcript, slides, and related documents.
A.G.P. Virtual Consumer Showcase summary
12 Nov, 2026Business and research
Four business lines span consumer supplements and skincare, ingredient supply, Niagen Plus IV/injections, and pharmaceutical development.
Management cited 52 peer-reviewed clinical studies on NR and 30 more underway; it estimated the global NAD supplement market at $3B, versus $10M 8–10 years earlier.
Management positioned NR as its preferred NAD precursor and cited a Norway study finding NR 2.3x more effective than NMN at elevating NAD.
Consumer products and marketing
Tru Niagen is a ~$100M supplement, sold mainly through Amazon and its website, with Watsons in parts of Asia and limited U.S. retail; Nestlé and Life Extension also sell NR products.
Direct website sales grew more than 30% last year, while sales were flat this year amid lower-priced competitors; management expects supplement growth to resume as awareness and product range expand.
NanoCloud skincare launched after studies indicated topical NR penetrates skin and raises NAD in skin cells; management expects a major skincare partner to launch a widely distributed product in Q1 next year.
Marketing investment has increased and could remain elevated for one or two quarters; a Kelly Slater campaign is intended to build brand awareness.
Ingredient and delivery businesses
Ingredient customers include Nestlé, H&H, and Life Extension; a Goli NR gummy was expected to launch shortly.
Nicotinamide riboside malate is a lower-cost ingredient intended for broader supply to supplement brands; whether to launch it under Tru Niagen remained under review.
Niagen Plus offers pharmaceutical-grade NR through clinics and at-home injection kits; management described the kits as selling, while its plans for aggressive investment in the channel remained undecided.
Latest events from Niagen Bioscience
- TRU NIAGEN drove 49% FY sales growth, while losses widened and break-even remained a 2019/20 target.NAGE
Q4 2018 - TRU NIAGEN drove 47% FY sales growth as margins improved and global expansion continued.NAGE
Q4 2019 - Q4 growth and stronger margins advanced the path toward break-even.NAGE
Q4 2020 - A profitable NAD+ platform is funding expansion into IVs, skincare, and therapeutics.NAGE
Corporate presentation - Q3 sales fell 20% as investment and new launches targeted future growth.NAGE
Q3 2026 - Rare-disease drug ambitions extend a profitable NAD platform into new channels.NAGE
LD Micro 20th Annual Main Event Conference - Strong growth, innovation, and a leading NAD drug pipeline position the company for future success.NAGE
17th Annual Midwest IDEAS Conference - Strong NAD+ supplement sales, new skincare launches, and robust cash flow support biotech growth.NAGE
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 delivered $29.8M sales, $1M net income, and major telehealth and pharma launches.NAGE
Q2 2026